Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
返回论文页
Review article|更新时间:2023-08-29
|
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Genes & DiseasesVol. 10, Issue 3, (2023)
作者机构:
1. Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Shanghai,China,200233
2. School of Kinesiology, Shanghai University of Sport,Shanghai,China,200438
Yao Zhang, Yibing Wang, Junli Liu. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective. [J]. Genes & Diseases 10(3).(2023)
DOI:
Yao Zhang, Yibing Wang, Junli Liu. Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective. [J]. Genes & Diseases 10(3).(2023) DOI: 10.1016/j.gendis.2021.12.011.
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
摘要
Abstract
Due to excess energy intake and a sedentary lifestyle
the prevalence of obesity is rising steadily and has emerged as a global public health problem. Adipose tissue undergoes structural remodeling and dysfunction in the obese state. Secreted proteins derived from the liver
also termed as hepatokines
exert multiple effects on adipose tissue remodeling and the development of obesity
and has drawn extensive attention for their therapeutic potential in the treatment of obesity and related diseases. Several novel hepatokines and their functions on systemic metabolism have been interrogated recently as well. The drug development programs targeting hepatokines also have shown inspiring benefits in obesity treatment. In this review
we outline how adipose tissue changes during obesity. Then
we summarize and critically analyze the novel findings on the effects of metabolic “beneficial” and metabolic “harmful” hepatokines to adipose tissue. We also discuss the in-depth molecular mechanism that hepatokines may mediate the liver-adipose tissue crosstalk
the novel technologies targeting hepatokines and their receptors
in vivo
to explore their functions
and the potential application of these interventions in clinical practice.